Page 542 - medicina-integrativa_compress

CAPÍTULO 49 ENFERMEDAD INFLAMATORIA INTESTINAL 547

82. Wright JP, Mee AS, Parfitt A, et al: Vitamin A therapy in patients 107. Ravina A, Slezak L, Mirsky N, et al: Reversal of corticosteroid-
with Crohn’s disease. Gastroenterology 88:512-514, 1985. induced diabetes mellitus with supplemental chromium. Diabet Med
83. Norrby S, Sjodahl R, Tagesson C: Ineffectiveness of vitamin A 16:164-167, 1999.
therapy in severe Crohn’s disease. Acta Chir Scand 151:465-468, 108. Gasche C, Lomer MC, Cavill I, Weiss G: Iron, anaemia, and
1985. inflammatory bowel diseases. Gut 53:1190-1197, 2004.
84. Harries AD, Brown R, Heatley RV, et al: Vitamin D status in 109. Oldenburg B, Koningsberger JC, Van Berge Henegouwen GP, et al:
Crohn’s disease: Association with nutrition and disease activity. Iron and inflammatory bowel disease. Aliment Pharmacol Ther
Gut 26:1197-1203, 1985. 15:429-438, 2001.
85. Vogelsang H, Ferenci P, Woloszczuk W, et al: Bone disease in 110. Siguel EN, Lerman RH: Prevalence of essential fatty acid deficiency
vitamin D-deficient patients with Crohn’s disease. Dig Dis Sci in patients with chronic gastrointestinal disorders. Metabolism
34:1094-1099, 1989. 45:12-23, 1996.
86. Vogelsang H, Ferenci P, Resch H, et al: Prevention of bone mineral 111. Vanderhoof JA, Blackwood DJ, Mohammadpour H, Park JH: Effect
loss in patients with Crohn’s disease by long-term oral vitamin D of dietary menhaden oil on normal growth and development and on
supplementation. Eur J Gastroenterol Hepatol 7:609-614, 1995. ameliorating mucosal injury in rats. Am J Clin Nutr 54:346-350,
87. Trebble TM, Wootton SA, Stroud MA, et al: Laboratory markers 1991.
predict bone loss in Crohn’s disease: Relationship to blood 112. Ruthig DJ, Meckling-Gill KA: Both omega-3 and omega-6 fatty acids
mononuclear cell function and nutritional status. Aliment stimulate wound healing in the rat intestinal epithelial cell line, IEC-
Pharmacol Ther 19:1063-1071, 2004. 6. J Nutr 129:1791-1798, 1999.
88. Abreu MT, Kantorovich V, Vasiliauskas EA, et al: Measurement 113. Stenson WF, Cort D, Rodgers J, et al: Dietary supplementation with
of vitamin D levels in inflammatory bowel disease patients fish oil in ulcerative colitis. Ann Intern Med 116:609-615, 1992.
reveals a subset of Crohn’s disease patients with elevated 114. Almallah YZ, Ewen SW, El-Tahir A, et al: Distal proctocolitis and
1,25-dihydroxyvitamin D and low bone mineral density. n-3 polyunsaturated fatty acids (n-3 PUFAs): The mucosal effect in
Gut 53:1129-1136, 2004. situ. J Clin Immunol 20:68-76, 2000.
89. Tuohy KA, Steinman TI: Hypercalcemia due to excess 115. Aslan A, Triadafilopoulos G: Fish oil fatty acid supplementation in
1,25-dihydroxyvitamin D in Crohn’s disease. Am J Kidney Dis active ulcerative colitis: A double-blind, placebo-controlled,
45:e3-6, 2005. crossover study. Am J Gastroenterol 87:432-437, 1992.
90. Krasinski SD, Russell RM, Furie BC, et al: The prevalence of vitamin 116. Loeschke K, Ueberschaer B, Pietsch A, et al: Omega-3 fatty acids
K deficiency in chronic gastrointestinal disorders. Am J Clin Nutr retard early relapse in ulcerative colitis in remission. Dig Dis Sci
41:639-643, 1985. 41:2087-2094, 1996.
91. Schoon EJ, Muller MC, Vermeer C, et al: Low serum and bone 117. Belluzzi A, Brignola C, Campieri M, et al: Effect of an enteric coated
vitamin K status in patients with longstanding Crohn’s disease: fish-oil preparation on relapses in Crohn’s disease. N Engl J Med
Another pathogenetic factor of osteoporosis in Crohn’s disease? 334:1557-1560, 1996.
Gut 48:473-477, 2001. 118. van der Hulst RR, van Kreel BK, von Meyenfeldt MF, et al:
92. Duggan P, O’Brien M, Kiely M, et al: Vitamin K status in patients Glutamine and the preservation of gut integrity. Lancet 341:
with Crohn’s disease and relationship to bone turnover. Am J 1363-1365, 1993.
Gastroenterol 99:2178-2185, 2004. 119. Akobeng AK, Miller V, Stanton J, et al: Double-blind randomized
93. Fugate SE, Ramsey AM: Resistance to oral vitamin K for reversal controlled trial of glutamine-enriched polymeric diet in the
of overanticoagulation during Crohn’s disease relapse. J Thromb treatment of active Crohn’s disease. J Pediatr Gastroenterol
Thrombolysis 17:219-223, 2004. Nutr 30:78-84, 2000.
94. Bernstein CN, Seeger LL, Anton PA, et al: A randomized, 120. Den Hond E, Hiele M, Peeters M, et al: Effect of long-term oral
placebo-controlled trial of calcium supplementation for decreased glutamine supplements on small intestinal permeability in patients
bone density in corticosteroid-using patients with inflammatory with Crohn’s disease. JPEN J Parenter Enteral Nutr 23:7-11, 1999.
bowel disease: A pilot study. Aliment Pharmacol Ther 10:777-786, 121. Shinozaki M, Saito H, Muto T: Excess glutamine exacerbates
1996. trinitrobenzenesulfonic acid-induced colitis in rats. Dis Colon
95. Cantorna MT, Zhu Y, Froicu M, Wittke A: Vitamin D status, Rectum 40(Suppl):S59-S63, 1997.
1,25-dihydroxyvitamin D 3 , and the immune system. Am J Clin 122. Burton AF, Anderson FH: Decreased incorporation of
Nutr 80(Suppl):1717S-1720S, 2004. 14C-glucosamine relative to 3 H-N-acetyl glucosamine in the
96. Griffin IJ, Kim SC, Hicks PD, et al: Zinc metabolism in adolescents intestinal mucosa of patients with inflammatory bowel disease.
with Crohn’s disease. Pediatr Res 56:235-239, 2004. Am J Gastroenterol 78:19-22, 1983.
97. Hendricks KM, Walker WA: Zinc deficiency in inflammatory bowel 123. Ryder SD, Raouf AH, Parker N, et al: Abnormal mucosal
disease. Nutr Rev 46:401-408, 1988. glycoprotein synthesis in inflammatory bowel diseases is not
98. Sturniolo GC, Di Leo V, Ferronato A, et al: Zinc supplementation related to cigarette smoking. Digestion 56:370-376, 1995.
© Elsevier. Es una publicación MASSON. Fotocopiar sin autorización es un delito.
tightens “leaky gut” in Crohn’s disease. Inflamm Bowel Dis 7:94-98, 124. Salvatore S, Heuschkel R, Tomlin S, et al: A pilot study of N-acetyl
2001. glucosamine, a nutritional substrate for glycosaminoglycan
99. Brignola C, Belloli C, De Simone G, et al: Zinc supplementation synthesis, in paediatric chronic inflammatory bowel disease. Aliment
restores plasma concentrations of zinc and thymulin in patients Pharmacol Ther 14:1567-1579, 2000.
with Crohn’s disease. Aliment Pharmacol Ther 7:275-280, 1993. 125. de la Torre B, Hedman M, Befrits R, et al: Blood and tissue
100. Reimund JM, Hirth C, Koehl C, et al: Antioxidant and immune dehydroepiandrosterone sulphate levels and their relationship
status in active Crohn’s disease: A possible relationship. Clin Nutr to chronic inflammatory bowel disease. Clin Exp Rheumatol 16:
19:43-48, 2000. 579-582, 1998.
101. Geerling BJ, Badart-Smook A, van Deursen C, et al: Nutritional 126. Straub RH, Vogl D, Gross V, et al: Association of humoral markers
supplementation with N-3 fatty acids and antioxidants in patients of inflammation and dehydroepiandrosterone sulfate or cortisol
with Crohn’s disease in remission: Effects on antioxidant status and serum levels in patients with chronic inflammatory bowel disease.
fatty acid profile. Inflamm Bowel Dis 6:77-84, 2000. Am J Gastroenterol 93:2197-2202, 1998.
102. Rannem T, Ladefoged K, Hylander E, et al: Selenium status in 127. Szathmari M, Vasarhelyi B, Treszl A, et al: Association of
patients with Crohn’s disease. Am J Clin Nutr 56:933-937, 1992. dehydroepiandrosterone sulfate and testosterone deficiency
103. Kuroki F, Matsumoto T, Iida M: Selenium is depleted in Crohn’s with bone turnover in men with inflammatory bowel disease.
disease on enteral nutrition. Dig Dis 21:266-270, 2003. Int J Colorectal Dis 17:63-66, 2002.
104. Galland L: Magnesium and inflammatory bowel disease. Magnesium 128. Andus T, Klebl F, Rogler G, et al: Patients with refractory Crohn’s
7:78-83, 1988. disease or ulcerative colitis respond to dehydroepiandrosterone:
105. Bohles H, Beifuss OJ, Brandl U, et al: Urinary factors of kidney stone A pilot study. Aliment Pharmacol Ther 17:409-414, 2003.
formation in patients with Crohn’s disease. Klin Wochenschr 66: 129. Klebl FH, Bregenzer N, Rogler G, et al: Treatment of pouchitis with
87-91, 1988. dehydroepiandrosterone (DHEA): A case report. Z Gastroenterol
106. McConnell N, Campbell S, Gillanders I, et al: Risk factors for 41:1087-1090, 2003.
developing renal stones in inflammatory bowel disease. BJU Int 130. O’Sullivan GC, Kelly P, O’Halloran S, et al: Probiotics: An emerging
89:835-841, 2002. therapy. Curr Pharm Des 11:3-10, 2005.